High-precision diagnostic systems are large and expensive, are mainly used in centralised laboratories and entail waiting and travel times of days. But if rapid test results are important or investment in a laboratory is not possible, such as in developing countries, point-of-care tests are an option. Yet in most cases, these are still too inaccurate and not digitised.
We are researching CMOS-integrated transducers and their interaction with biological receptors.
By integrating a wide range of functions and miniaturisation, as well as economies of scale, they offer the potential for precise, digital and at the same time cost-effective point-of-care tests. With CMOS-based biosensors, structural sizes in the µm range can be achieved and thus properties can also be recorded on a molecular scale. Our focus is on sensors for optical (e.g. using SPADs) and charge-based (using ISFET) analysis methods.
Together with partners, we are researching the functionalisation of chip surfaces to be able to digitise other physical, chemical and biological parameters.
We are also researching the integration of ICs with other diagnostic technologies, such as microfluidic lab-on-chip systems.
Eric Schäfer, M. Sc.
Head of Microelectronics / Branch Office Erfurt
eric.schaefer(at)imms.de+49 (0) 361 663 25 35
Eric Schäfer and his team research Integrated sensor systems, especially CMOS-based biosensors, ULP sensor systems and AI-based design and test automation. The results are being incorporated into research on the lead applications Sensor systems for in-vitro diagnostics and RFID sensor technology. It will assist you with services for the development of Integrated circuits and with IC design methods.
IMMS is researching an integrated circuit for miniaturised, fast and broadband impedance analyses, e.g. on biosensors.
For an innovative rapid test for fertility diagnostics, IMMS is developing an image sensor for time-resolved fluorescence measurement.
IMMS has developed a chip for mobile diagnostic systems for the early detection of diseases using time-resolved fluorescence measurements.
We have developed a CMOS biochip with which the prostate-specific antigen can be quantitatively detected. The chip achieves the specifications required for clinical PSA tests according to Rili-BÄK for early cancer detection.
Dr. Friedrich Scholz, Senova
“IMMS demonstrated great commitment in responding to the huge challenges on the development of the point-of-care test. Our experience demonstrates that IMMS application-oriented analyses, understands and models the biochemical processes. Furthermore, the colleagues implement the specifications with their integrated system design and are flexible in adapting the systems as necessary.”